Ultimately, who is a good candidate for GLP-1 will depend on the specific inclusion and exclusion criteria of each trialbut in general, those struggling with weight-related health conditions and willing to engage in medical research are strong candidates
One of the innovative solutions we offer is Ozempic, a leading medication that has gained significant attention for its remarkable effectiveness in weight management and overall health improvement
Key findings for semaglutide duration include continued weight loss through at least 68 weeks with no plateau in many patients, weight regain of approximately 40% of lost weight within seven months of stopping, and withdrawal effects including increased appetite, food cravings, and in some cases gastrointestinal changes
This has led to increased interest in GLP-1 drugs for weight management, even among non-diabetics
Sustained release strategy designed for lixisenatide delivery to synchronously treat diabetes and associated complications
2 Monotherapy is no longer available in the USA since Jan 2023, and lixisenatide-glargine (iGlarLixi) has been approved for type 2 diabetes
